Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Extract of leontopodic acid plant and application of active ingredients thereof in treating hepatitis

A technology of plant extracts and active ingredients, applied in the field of preparation of drugs for the treatment of hepatitis B, can solve the problem that there are no anti-hepatitis drugs of edelweisin compounds

Inactive Publication Date: 2013-10-23
CHINA JILIANG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Literature search shows that so far, there is no report of edelweisin compounds and plant extracts containing edelweisin compounds for treating hepatitis and preparing anti-hepatitis drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Extract of leontopodic acid plant and application of active ingredients thereof in treating hepatitis
  • Extract of leontopodic acid plant and application of active ingredients thereof in treating hepatitis
  • Extract of leontopodic acid plant and application of active ingredients thereof in treating hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: Inhibition of Edelweiss plant extracts on HepG2.2.15 cells secreting hepatitis B virus surface antigen (HBsAg), hepatitis B virus E antigen (HBeAg) and hepatitis B virus DNA (HBV-DNA).

[0021] Determination of the inhibitory effect of the sample on the growth of HepG2.2.15 cells: the cells were digested with trypsin-EDTA and diluted to 1×10 5 / mL, added to a 96-well cell culture plate, 100uL per well, placed in CO 2cultured in an incubator. After 24 hours of inoculation, discard the medium, add the sample diluted with the medium, 200ul per well, add 3 wells for each concentration, add 5mg / ml MTT to the cell culture wells after 72 hours of culture, 10ul per well, and place at 37°C After incubation for 3 hours, 150ul of DMSO was added to completely dissolve the formazan, and a microplate reader was used for colorimetry at a wavelength of 570nm. Calculate the median toxic concentration of the sample on the growth of HepG2.2.15 cells.

[0022] Determination o...

Embodiment 2

[0027] Example 2 Effect of Edelweiss plant extract on D-GalN-induced liver cell damage

[0028] Human normal liver cell line HL-7702, placed at 37°C in CO 2 Culture in an incubator; after the hepatocytes adhered to the wall, replace the culture medium, add 200mmol / l D-GalN, and act for 8h; then discard the culture medium, and add 200μl of different concentrations of the test drug solution, each concentration was set at 6 Repeat wells, set solvent and positive control at the same time; continue to culture for 48h, add 10μl MTT (5mg / ml) to each well, act for 4h, aspirate and discard the supernatant, add 150μl DMSO, shake and mix well; The instrument measures the A value.

[0029] Protection evaluation: calculation of protection rate (%) and proliferation index.

[0030]

[0031] Note 2: Proliferation index = sample group (A) / injury group (A)

[0032] Table 2 Effects of Edelweiss plant extracts on human normal liver cell damage induced by D-GalN

[0033]

[0034] The re...

Embodiment 3

[0035] Example 3 Protective effect of edelweiss plant extract on D-GalN-induced acute liver injury model in mice

[0036] Materials: 20-25g male ICR mice were randomly divided into groups according to body weight, 10 mice in each group. A normal control group, an injury control group, a positive control group and high, medium and low dose groups of the test drug were set up. Animals in the drug group were given prophylactic administration once a day for 7 consecutive days. The normal control group and the injury control group were given an equal volume of solvent, and the positive control group was given 50 mg / kg of silymarin. One hour after the last administration, animals in each group except the normal group were injected with 650 mg / kg galactosamine (D-GalN) intraperitoneally to cause toxicity. 24 hours after the last administration, the serum was separated to measure aspartate aminotransferase (AST) and alanine aminotransferase (ALT). At the same time, liver tissue was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an extract of a leontopodic acid plant containing leontopodic acid compounds, leontopodic acid, a derivative the leontopodic acid, and application of a medicinal composition containing the leontopodic acid in treating hepatitis, particularly to application in preparing medicaments for treating hepatitis B. The leontopodic acid and the extract of a leontopodic acid plant containing leontopodic acid compounds have obvious effects on resisting hepatitis B virus, resisting inflammation, protecting the liver and regulating immunity, and can be used for treating hepatitis, particularly for treating diseases related to hepatitis B virus infection.

Description

technical field [0001] The present invention relates to the application of a plant extract and its active ingredients in the treatment of hepatitis, especially the edelweiss plant extract containing edelweisin compounds, edelweissin and its derivatives, and the drug combination containing edelweisin The use of the compound in the preparation of medicines for treating hepatitis B. Background technique [0002] Hepatitis is a general term for inflammatory diseases of the liver. According to the etiology, it can be divided into viral, alcoholic, drug-induced and autoimmune hepatitis. Viral hepatitis is the most common, of which hepatitis B is the main one, and hepatitis C next. Hepatitis B is a very harmful worldwide epidemic infectious disease caused by hepatitis B virus (HBV). According to statistics, there are currently about 350 million HBV carriers in the world, and China is a high-infection area of ​​HBV. HBV carriers Patients account for as high as 10% to 15% of the to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/216A61P1/16A61P31/20A61P37/02C07C69/732C07C67/48
Inventor 伍义行郝冰洁
Owner CHINA JILIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com